On Friday's news that Biohaven (BHVN -15.34%) withdrew its application for a top investigational drug from an important ...

The drug, being developed for a rare genetic disorder and currently under review in the U.S., is seen by some investors as ...

RBC Capital after notes released by the European Medicines Agency’s CHMP indicated that Biohaven (BHVN) had withdrawn the application for ...

We recently published a list of Jim Cramer Recently Talked About These 15 Stocks. In this article, we are going to take a ...

EDT Biohaven (BHVN) down 12% to $20.60 after pulling European applicationStay Ahead of the Market: Discover outperforming stocks and ...

We recently published a list of 11 Best Guru Stocks to Buy According to Wall Street Analysts. In this article, we are going ...

Investing.com -- Biohaven Pharma (NYSE: BHVN) shares fell sharply by as much as 21% as the company withdrew its marketing authorization application for Dazluma in Europe, intended to treat ...

BHV-8000 from Biohaven Pharmaceuticals Inc. is a dual, brain-penetrant, oral small molecule that is highly selective against TYK2 and JAK1 enzymes, which are essential enzymes to the inflammatory ...

American Century Companies has boosted its stake in Biohaven (BHVN) by 9.5% during Q4, ETF Daily News reports, citing a recent SEC filing. The firm owned 558,761 shares of Biohaven after purchasing an ...

Biohaven Pharmaceuticals Inc. has presented preclinical data on their novel bispecific degrader BHV-1310 for the potential treatment of autoimmune disorders. To date, about 10% of the global ...

Biohaven Ltd. (NYSE:BHVN – Free Report) – Research analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Biohaven in a report issued on Sunday, April 13th.